Kleinjan, Jan P <br/><br/>
Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study.  [electronic resource] 

 -  Anti-cancer drugs  04 2019 
 - 410-415 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Observational Study 
<br/><br/><label>ISSN: </label>1473-5741 
<br/><br/><label>Standard No.: </label>10.1097/CAD.0000000000000748  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Capecitabine--administration & dosage<br/>Dihydrouracil Dehydrogenase (NADP)--genetics<br/>Female<br/>Follow-Up Studies<br/>Genotype<br/>Heterozygote<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Polymorphism, Single Nucleotide<br/>Practice Guidelines as Topic--standards<br/>Prognosis<br/>Retrospective Studies<br/>Survival Rate